Previous Close | 15.13 |
Open | 15.24 |
Bid | 15.47 x 800 |
Ask | 15.48 x 1400 |
Day's Range | 15.19 - 15.52 |
52 Week Range | 12.62 - 19.09 |
Volume | |
Avg. Volume | 1,402,038 |
Market Cap | 1.792B |
Beta (5Y Monthly) | 1.31 |
PE Ratio (TTM) | 5.58 |
EPS (TTM) | 2.77 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | 1.40 (8.80%) |
Ex-Dividend Date | Aug 08, 2022 |
1y Target Est | 17.39 |
Driven by the growing demand for customized financing, Hercules Capital's (HTGC) top line is expected to keep improving.
Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM)Q2 2022 Earnings CallAug 09, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the Axsome Therapeutics conference call.
-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA (samRNA) -- -- New credit facility provides financial flexibility entering period of multiple potent